COVID-19: Use rapid tests to identify important biomarkers and predict the course of the disease

Share

Whether it’s a lung embolism or a heart attack – an infection with coronavirus can have life-threatening consequences. But how badly will different patients be affected by COVID-19? This can be determined by certain biomarkers. nal von minden GmbH’s biomarker rapid tests from Germany deliver reliable results in just 15 minutes.

An infection with coronavirus can run different courses. Some of those affected display no symptoms, whereas in other patients the course of the disease can be so severe that for some it is even fatal. Biomarkers serve as a quantifiable indicator for the presence and severity of an infection. They can be identified and evaluated using a blood sample.

Studies have shown that the following biomarkers in particular play an important role in the prognosis of an infection with COVID-19: D-Dimer and troponin as well as C-reactive protein and the inflammatory marker procalcitonin. Raised D-Dimer levels are associated with deep vein thrombosis or a lung embolism, whereas elevated troponin levels indicate heart damage. Raised inflammatory markers have been identified in patients who have died.

 nal von minden GmbH has developed rapid tests for the most important biomarkers which can be carried out onsite. Reliable results are available after just 15 minutes. “The faster important biomarkers are determined, the sooner the correct – and potentially life-saving – treatment measures can be implemented”, says Roland Meißner, CEO of nal von minden GmbH. If blood samples need to be sent to an external laboratory for testing, hours or even days can be lost.

The biomarker rapid tests are suitable for both hospital emergency rooms and GP practices, where they serve to quickly clarify the health status of a patient infected with coronavirus. Results can immediately be discussed with the patient.

Roland Meißner: “We don’t view our tests as being in competition with laboratories, but rather as a valuable addition since laboratories are already overburdened. In the interests of patients, a decision regarding treatment must be made quickly.”

Contacts

Press contact: Gabriele Hellwig, +49 40 38 66 24 80, info@hellwig-pr.de

About nal von minden GmbH

nal von minden GmbH

Moers

Subscribe to releases from nal von minden GmbH

Subscribe to all the latest releases from nal von minden GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from nal von minden GmbH

Corona rapid test: Celebrate Christmas together without anyone getting infected15.12.2020 14:48:24 CETPressemeddelelse

In many places, uncertainty is now mixed in with the anticipation of Christmas: will Christmas be a “super spreader event” as many politicians are warning? “No”, Roland Meissner, the CEO of nal von minden in Moers, Germany is convinced: “you can protect your relatives as best as possible by getting tested for corona beforehand.” There are also tips to minimize the risk of corona during the actual festivities.

New study: Only reliable rapid corona tests make sense3.12.2020 11:58:51 CETPress release

More and more manufacturers are bringing corona rapid tests onto the market. But only if they provide reliable results does their use in the fight against the pandemic makes sense. The Charité hospital in Berlin, one of the largest university hospitals in Europe, has now reviewed the performance of corona antigen rapid tests. The corona rapid test from nal von minden GmbH proved to be particularly reliable. The NADAL® COVID-19 Ag rapid test has already been used millions of times throughout Europe during the corona pandemic and provides a result within only 15 minutes.

nal von minden plans to produce 80 million rapid corona tests per month20.11.2020 11:54:07 CETPress release

Rapid corona testing is playing an increasingly important role in containing the pandemic everywhere – even though the first vaccines are now in sight. The medical technology company nal von minden GmbH from Moers, Germany, is therefore doubling its production: 40 million rapid antigen tests are already being produced in November. By January, this figure is expected to rise to 80 million – every month!

New: Combined rapid test for Covid-19 and influenza2.11.2020 09:45:56 CETPress release

Corona numbers are rising, and the next challenge is already in sight: Flu season is beginning. The symptoms can be very similar, but a test can differentiate between influenza and Covid-19. A new combined rapid test can detect coronavirus and influenza viruses simultaneously: The NADAL® COVID-19 Ag+Influenza A/B Test from German medical technology company nal von minden delivers a reliable result in just 15 minutes.

New Covid-19 antigen test: Fast and reliable results in just 15 minutes26.10.2020 09:06:23 CETPress release

Preventing further spread of the coronavirus and taking pressure off laboratories – it is possible with the NADAL® Covid-19 Antigen Test from Germany. Whether in schools, nursing homes, hospitals, companies, or at the airport or larger events: The result is available in just 15 minutes. The new rapid test from medical technology company nal von minden GmbH is already approved in Europe and is available immediately. The high quality has been repeatedly verified.